This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dynavax Technologies (DVAX) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -8.33% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ChemoCentryx (CCXI) Q4 Earnings and Sales Miss Estimates
by Zacks Equity Research
ChemoCentryx (CCXI) posts a wider year-over-year loss in the fourth quarter and sales miss estimates. Lead drug Tavneos has been launched in the United States.
FATE's Loss Wider Than Expected in Q4, Pipeline in Focus
by Zacks Equity Research
FATE reports a wider loss on increased R&D expenses in the fourth quarter.
Endo (ENDP) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Endo (ENDP) tops Q4 earnings and sales estimates. However, Vasostrict faces generic competition, and the ongoing COVID-19 driven market conditions affect specialty product office-based procedures.
Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Acadia (ACAD) posts a wider-than-expected loss for the fourth quarter of 2021. Shares fall during the after-hours trading.
Apellis (APLS) Q4 Loss Widens, Revenues Surpass Estimates
by Zacks Equity Research
Apellis' (APLS) earnings miss estimates in the fourth quarter of 2021, while revenues surpass expectations.
Dynavax Technologies (DVAX) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -20.29% and 14.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Reata's (RETA) Q4 Earnings Miss Mark, Revenues Decline Y/Y
by Zacks Equity Research
Reata (RETA) reports a wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly lower than estimates.
Viatris' (VTRS) Q4 Earnings Miss, Biocon Biologics Deal Inked
by Zacks Equity Research
Viatris (VTRS) misses on Q4 earnings but surpasses sales estimates. The company announces a combination of its biosimilars portfolio with Biocon Biologics.
Editas' (EDIT) Q4 Loss Narrows, Revenues Trump Estimates
by Zacks Equity Research
Editas (EDIT) reports narrower-than-expected loss in the fourth quarter of 2021 while its revenues beat estimates. Focus remains on the development of lead candidate, EDIT-101.
Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates.
Bausch's (BHC) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the fourth quarter. The outlook for 2022 is disappointing.
Dynavax Technologies (DVAX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -6.74% and 10.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Dynavax's (DVAX) Growth Momentum Continue in 2022?
by Zacks Equity Research
Year-over-year revenue growth for HEPLISAV-B and CpG 1018 adjuvant is expected to drive Dynavax???s (DVAX) profitability in 2022.
Biogen (BIIB) Q4 Earnings Top, Stock Down on Weak 2022 View
by Zacks Equity Research
Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The stock declines on weak sales and earnings guidance for 2022.
Zacks Industry Outlook Highlights: Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen
by Zacks Equity Research
Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen are highlighted in this Industry Outlook article.
4 Top Biotech Stocks to Gain Amid Industry Challenges
by Ekta Bagri
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX and RGEN well amid the volatility.
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are likely to focus on Vertex Pharmaceuticals' (VRTX) CF product revenues, especially sales of its triple combo CF drug Trikafta/Kaftrio, and non-CF pipeline progress.
Amgen's (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer
by Zacks Equity Research
Amgen's (AMGN) KRAS inhibitor, Lumakras, gets approval in Japan for the treatment of KRAS G12C-mutated positive advanced/recurrent non-small-cell lung cancer.
Zealand (ZEAL) Ends Enrollment in Short Bowel Syndrome Study
by Zacks Equity Research
Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.
New Strong Buy Stocks for January 21st
by Zacks Equity Research
ARCB, BCC, DVAX, FCX, and JBHT have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2022.
Dynavax Technologies (DVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Dynavax Technologies (DVAX) closed at $14.07, marking a -1.05% move from the previous day.
Is Dynavax Technologies (DVAX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Dynavax Technologies (DVAX) and Omnicell (OMCL) have performed compared to their sector so far this year.
5 Biotech Stocks That More Than Doubled This Year
by Ekta Bagri
The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplary performance.